Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

William A. See MD

Chair, Professor

Institution: Medical College of Wisconsin
Department: Urologic Surgery
Program: Administration

Member of the Cancer Center


Publications

  • Toward Quantitative Whole Organ Thermoacoustics With a Clinical Array Plus One Very Low-Frequency Channel Applied to Prostate Cancer Imaging. (Patch SK, Hull D, See WA, Hanson GW) IEEE Trans Ultrason Ferroelectr Freq Control 2016 Feb;63(2):245-55 PMID: 26731749 PMCID: PMC4786189 01/06/2016
  • The Dose-Response Relationship of bacillus Calmette-Guérin and Urothelial Carcinoma Cell Biology. (Shah G, Zhang G, Chen F, Cao Y, Kalyanaraman B, See WA) J Urol 2016 Jun;195(6):1903-10 PMID: 26694905 12/24/2015
  • Initial experience with ketamine-based analgesia in patients undergoing robotic radical cystectomy and diversion. (Jacobsohn K, Davis TD, El-Arabi AM, Tlachac J, Langenstroer P, O'Connor RC, Guralnick ML, See WA, Schlosser R) Can Urol Assoc J 2015 May-Jun;9(5-6):E367-71 PMID: 26225179 PMCID: PMC4479652 08/01/2015
  • Thermoacoustic contrast of prostate cancer due to heating by very high frequency irradiation. (Patch SK, Hull D, Thomas M, Griep SK, Jacobsohn K, See WA) Phys Med Biol 2015 Jan 21;60(2):689-708 PMID: 25554968 PMCID: PMC4292912 01/03/2015
  • Commentary on "Outpatient laser ablation of non-muscle-invasive bladder cancer: is it safe, tolerable and cost-effective?" Wong KA, Zisengwe G, Athanasiou T, O'Brien T, Thomas K, The Urology Centre, Guys and St. Thomas' NHS Foundation Trust.: BJU Int 2013; 112(5):561-7. doi:10.1111/bju.12216. [Epub 2013 Jul 2]. (See WA) Urol Oncol 2014 Nov;32(8):1350-1 PMID: 25488386 12/10/2014
  • Commentary on "Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle." Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam Hospital, Amsterdam, The Netherlands.: BJU Int 2013; 112(6):72934. doi:10.1111/bju.12109. [Epub 2013 Jun 24]. (See WA) Urol Oncol 2014 Nov;32(8):1350 PMID: 25488385 12/10/2014
  • Commentary on "Optimal schedule of bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: A meta-analysis of comparative studies." Zhu S, Tang Y, Li K, Shang Z, Jiang N, Nian X, Sun L, Niu Y, Department of Urology Tianjin Institute of Urology, 2nd Hospital of Tianjin Medical University, People's Republic of China.: BMC Cancer 2013; 13:332. doi:10.1186/1471-2407-13-332. (See WA) Urol Oncol 2014 Nov;32(8):1349-50 PMID: 25488384 12/10/2014
  • Commentary on "Robot-assisted laparoscopic vs open radical cystectomy: Comparison of complications and perioperative oncological outcomes in 200 patients." Kader AK, Richards KA, Krane LS, Pettus JA, Smith JJ, Hemal AK, Division of Urology, UC San Diego Health System, San Diego, CA.: BJU Int 2013; 112(4):E290-4. doi:10.1111/bju.12167. [Epub 2013 Jul 1]. (See WA) Urol Oncol 2014 Nov;32(8):1348 PMID: 25488382 12/10/2014
  • A comparison of case volumes among urologic surgeons identified on an industry-sponsored website to an all provider peer group. (See WA, Jacobson K, Derus S, Langenstroer P) Urol Oncol 2014 Nov;32(8):1095-100 PMID: 25260903 09/28/2014
  • Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217). (Gritz ER, Arnold KB, Moinpour CM, Burton-Chase AM, Tangen CM, Probstfield JF, See WA, Lieber MM, Caggiano V, Moody-Thomas S, Szczepanek C, Ryan A, Carlin S, Hill S, Goodman PJ, Padberg RM, Minasian LM, Meyskens FL, Thompson IM Jr) Cancer Epidemiol Biomarkers Prev 2014 Aug;23(8):1638-48 PMID: 25028457 PMCID: PMC4119542 07/17/2014
  • Senior medical student opinions regarding the ideal urology interview day. (Jacobs JC, Guralnick ML, Sandlow JI, Langenstroer P, Begun FP, See WA, O'Connor RC) J Surg Educ 2014 Nov-Dec;71(6):878-82 PMID: 24981655 07/02/2014
  • H2O2 generation by bacillus Calmette-Guérin induces the cellular oxidative stress response required for bacillus Calmette-Guérin direct effects on urothelial carcinoma biology. (Shah G, Zielonka J, Chen F, Zhang G, Cao Y, Kalyanaraman B, See W) J Urol 2014 Oct;192(4):1238-48 PMID: 24928267 06/15/2014
  • Immediate total parenteral nutrition after radical cystectomy and urinary diversion. (Pham KN, Schwartz LW, Garg T, Langenstroer P, Guralnick ML, See WA, O'Connor RC) WMJ 2014 Feb;113(1):20-3 PMID: 24712216 04/10/2014
  • Re: use of advanced treatment technologies among men at low risk of dying from prostate cancer. (See WA) Eur Urol 2014 Jan;65(1):250 PMID: 24289855 12/03/2013
  • V-Loc urethro-intestinal anastomosis during robotic cystectomy with orthotopic urinary diversion. (Pham KN, Sack BS, O'Connor RC, Guralnick ML, Langenstroer P, See WA, Jacobsohn K) Can Urol Assoc J 2013 Nov-Dec;7(11-12):E663-6 PMID: 24282453 PMCID: PMC3840523 11/28/2013
  • iNOS expression and NO production contribute to the direct effects of BCG on urothelial carcinoma cell biology. (Shah G, Zhang G, Chen F, Cao Y, Kalyanaraman B, See WA) Urol Oncol 2014 Jan;32(1):45.e1-9 PMID: 24054867 09/24/2013
  • A manpower calculus: the implications of SUO fellowship expansion on oncologic surgeon case volumes. (See WA) Urol Oncol 2014 Jan;32(1):42.e7-12 PMID: 23911685 08/06/2013
  • Commentary on "Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome." Win AK, Lindor NM, Young JP, Macrae FA, Young GP, Williamson E, Parry S, Goldblatt J, Lipton L, Winship I, Leggett B, Tucker KM, Giles GG, Buchanan DD, Clendenning M, Rosty C, Arnold J, Levine AJ, Haile RW, Gallinger S, Le Marchand L, Newcomb PA, Hopper JL, Jenkins MA, Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, Melbourne School of Population Health, The University of Melbourne, Victoria, Australia: J Natl Cancer Inst 2012;104(18):1363-72 [Epub 2012 Aug 28]. (See WA) Urol Oncol 2013 Jul;31(5):716 PMID: 23796201 06/26/2013
  • Commentary on "Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?" Mertens LS, Meijer RP, Kerst JM, Bergman AM, van Tinteren H, van Rhijn BW, Horenblas S, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands: J Urol 2012;188(4):1108-13 [Epub 2012 Aug 15]. (See WA) Urol Oncol 2013 Jul;31(5):716-7 PMID: 23796200 06/26/2013
  • Commentary on "A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin." Kowalski M, Guindon J, Brazas L, Moore C, Entwistle J, Cizeau J, Jewett MA, MacDonald GC: J Urol 2012;188(5):1712-8 [Epub 2012 Sep 19]. (See WA) Urol Oncol 2013 Jul;31(5):714 PMID: 23796197 06/26/2013
  • Commentary on "Plasma carotenoids and vitamin C concentrations and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and Nutrition." Ros MM, Bueno de Mesquita HB, Kampman E, Aben KK, Büchner FL, Jansen EH, van Gils CH, Egevad L, Overvad K, Tjønneland A, Roswall N, Boutron Ruault MC, Kvaskoff M, Perquier F, Kaaks R, Chang Claude J, Weikert S, Boeing H, Trichopoulou A, Lagiou P, Dilis V, Palli D, Pala V, Sacerdote C, Tumino R, Panico S, Peeters PH, Gram IT, Skeie G, Huerta JM, Barricarte A, Quirós JR, Sánchez MJ, Buckland G, Larrañaga N, Ehrnström R, Wallström P, Ljungberg B, Hallmans G, Key TJ, Allen NE, Khaw KT, Wareham N, Brennan P, Riboli E, Kiemeney LA, National Institute for Public Health and the Environment, Bilthoven, Netherlands: Am J Clin Nutr 2012;96(4):902-10 [Epub 2012 Sep 5]. (See WA) Urol Oncol 2013 Jul;31(5):714-5 PMID: 23796198 06/26/2013
  • Commentary on "The value of transurethral bladder biopsy after intravesical bacillus Calmette-Guérin instillation therapy for nonmuscle invasive bladder cancer: a retrospective, single center study and cumulative analysis of the literature." Swietek N, Waldert M, Rom M, Schatzl G, Wiener HG, Susani M, Klatte T. Department of Urology, Medical University of Vienna, Vienna, Austria: J Urol 2012;188(3):748-53 [Epub 2012 Jul 20]. (See WA) Urol Oncol 2013 Jul;31(5):715-6 PMID: 23796199 06/26/2013
  • Duloxetine for the treatment of post-prostatectomy stress urinary incontinence. (Neff D, Guise A, Guralnick ML, Langenstroer P, See WA, Jacobsohn KM, O'Connor RC) Can Urol Assoc J 2013 May-Jun;7(5-6):E260-2 PMID: 23766826 PMCID: PMC3668403 06/15/2013
  • Contributors to HMGB1 release by urothelial carcinoma cells in response to bacillus Calmette-Guérin. (Zhang G, Chen F, Cao Y, See WA) J Urol 2013 Oct;190(4):1398-403 PMID: 23583857 04/16/2013
  • HMGB1 release by urothelial carcinoma cells in response to Bacillus Calmette-Guérin functions as a paracrine factor to potentiate the direct cellular effects of Bacillus Calmette-Guérin. (Zhang G, Chen F, Cao Y, Amos JV, Shah G, See WA) J Urol 2013 Sep;190(3):1076-82 PMID: 23353043 01/29/2013
  • Pharmacokinetics of protocatechuic acid in mouse and its quantification in human plasma using LC-tandem mass spectrometry. (Chen W, Wang D, Wang LS, Bei D, Wang J, See WA, Mallery SR, Stoner GD, Liu Z) J Chromatogr B Analyt Technol Biomed Life Sci 2012 Nov 01;908:39-44 PMID: 23122399 PMCID: PMC3538353 11/06/2012
  • HMGB1 release by urothelial carcinoma cells is required for the in vivo antitumor response to Bacillus Calmette-Guérin. (Zhang G, Chen F, Cao Y, Johnson B, See WA) J Urol 2013 Apr;189(4):1541-6 PMID: 23041342 10/09/2012
  • A synthetic polyvalent ligand for α5β1 integrin activates components of the urothelial carcinoma cell response to bacillus Calmette-Guérin. (Chen F, Zhang G, Cao Y, Wakim B, See WA) J Urol 2013 Mar;189(3):1104-9 PMID: 22999999 09/25/2012
  • Words of wisdom. Re: Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. (See WA) Eur Urol 2012 May;61(5):1066 PMID: 22469416 04/04/2012
  • Specific heat capacity of freshly excised prostate specimens. (Patch SK, Rao N, Kelly H, Jacobsohn K, See WA) Physiol Meas 2011 Nov;32(11):N55-64 PMID: 22027030 10/27/2011
  • The association of robotic surgical technology and hospital prostatectomy volumes: increasing market share through the adoption of technology. (Neuner JM, See WA, Pezzin LE, Tarima S, Nattinger AB) Cancer 2012 Jan 15;118(2):371-7 PMID: 21717434 07/01/2011
  • Ex vivo thermoacoustic imaging over large fields of view with 108 MHz irradiation. (Eckhart AT, Balmer RT, See WA, Patch SK) IEEE Trans Biomed Eng 2011 Aug;58(8) PMID: 21421431 03/23/2011
  • Assessment and management of irritative voiding symptoms. (Guralnick ML, O'Connor RC, See WA) Med Clin North Am 2011 Jan;95(1):121-7 PMID: 21095416 11/26/2010
  • Re: Comparative effectiveness of prostate cancer surgical treatments: a population based analysis of postoperative outcomes: W. T. Lowrance, E. B. Elkin, L. M. Jacks, D. S. Yee, T. L. Jang, V. P. Laudone, B. D. Guillonneau, P. T. Scardino and J. A. Eastham J Urol 2010; 183: 1366-1372. (See WA) J Urol 2010 Oct;184(4):1573-4; author reply 1574 PMID: 20732691 08/25/2010
  • Candidate urinary biomarker discovery in ureteropelvic junction obstruction: a proteomic approach. (Mesrobian HG, Mitchell ME, See WA, Halligan BD, Carlson BE, Greene AS, Wakim BT) J Urol 2010 Aug;184(2):709-14 PMID: 20639044 07/20/2010
  • Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. (Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP, Casodex Early Prostate Cancer Trialists' Group) BJU Int 2010 Apr;105(8):1074-81 PMID: 22129214 04/01/2010
  • MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin. (Chen F, Zhang G, Cao Y, Hessner MJ, See WA) J Urol 2009 Dec;182(6):2932-7 PMID: 19853870 10/27/2009
  • Laparoscopic mesh herniorrhaphy: impact on outcomes associated with radical retropubic prostatectomy. (Neff DA, See WA) Urol Oncol 2011 Jan-Feb;29(1):66-9 PMID: 19837615 10/20/2009
  • Resonance metallic ureteral stents do not successfully treat ureteroenteric strictures. (Garg T, Guralnick ML, Langenstroer P, See WA, Hieb RA, Rilling WS, Sudakoff GS, O'Connor RC) J Endourol 2009 Jul;23(7):1199-201; discussion 1202 PMID: 19530950 06/18/2009
  • p21 Expression by human urothelial carcinoma cells modulates the phenotypic response to BCG. (See WA, Zhang G, Chen F, Cao Y) Urol Oncol 2010 Sep-Oct;28(5):526-33 PMID: 19450997 05/20/2009
  • Bladder neck contracture after radical retropubic prostatectomy using an intussuscepted vesico-urethral anastomosis: incidence with long-term follow-up. (Garg T, See WA) BJU Int 2009 Oct;104(7):925-8 PMID: 19389011 04/25/2009
  • Bacille-Calmette Guèrin induces caspase-independent cell death in urothelial carcinoma cells together with release of the necrosis-associated chemokine high molecular group box protein 1. (See WA, Zhang G, Chen F, Cao Y, Langenstroer P, Sandlow J) BJU Int 2009 Jun;103(12):1714-20 PMID: 19154459 01/22/2009
  • SmgGDS is up-regulated in prostate carcinoma and promotes tumour phenotypes in prostate cancer cells. (Zhi H, Yang XJ, Kuhnmuench J, Berg T, Thill R, Yang H, See WA, Becker CG, Williams CL, Li R) J Pathol 2009 Feb;217(3):389-97 PMID: 18973191 11/01/2008
  • Multidetector computerized tomography urography as the primary imaging modality for detecting urinary tract neoplasms in patients with asymptomatic hematuria. (Sudakoff GS, Dunn DP, Guralnick ML, Hellman RS, Eastwood D, See WA) J Urol 2008 Mar;179(3):862-7; discussion 867 PMID: 18221955 01/29/2008
  • Bacillus Calmette-Guerin inhibits apoptosis in human urothelial carcinoma cell lines in response to cytotoxic injury. (Chen F, Zhang G, Cao Y, Payne R, See WA) J Urol 2007 Nov;178(5):2166-70 PMID: 17870116 09/18/2007
  • Bacillus Calmette-Guérin induces p21 expression in human transitional carcinoma cell lines via an immediate early, p53 independent pathway. (Zhang G, Chen F, Cao Y, See WA) Urol Oncol 2007 May-Jun;25(3):221-7 PMID: 17483019 05/08/2007
  • Quantifying the natural history of post-radical prostatectomy incontinence using objective pad test data. (Smither AR, Guralnick ML, Davis NB, See WA) BMC Urol 2007 Feb 05;7:2 PMID: 17280607 PMCID: PMC1800860 02/07/2007
  • Bicalutamide adjuvant to radical prostatectomy. (See WA) Rev Urol 2004;6 Suppl 2:S20-8 PMID: 16985857 PMCID: PMC1472855 09/21/2006
  • The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. (See WA, Tyrrell CJ, CASODEX Early Prostate Cancer Trialists' Group) J Cancer Res Clin Oncol 2006 Aug;132 Suppl 1:S7-16 PMID: 16896884 08/10/2006
  • The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. (McLeod DG, See WA, Klimberg I, Gleason D, Chodak G, Montie J, Bernstein G, Morris C, Armstrong J) J Urol 2006 Jul;176(1):75-80 PMID: 16753373 06/07/2006
  • Are bone scans necessary in men with low prostate specific antigen levels following localized therapy? (Warren KS, Chodak GW, See WA, Iverson P, McLeod D, Wirth M, Morris C, Armstrong J) J Urol 2006 Jul;176(1):70-3; discussion 73-4 PMID: 16753371 06/07/2006
  • Intermediate results of laparoscopic cryoablation in 59 patients at the Medical College of Wisconsin. (Lawatsch EJ, Langenstroer P, Byrd GF, See WA, Quiroz FA, Begun FP) J Urol 2006 Apr;175(4):1225-9; discussion 1229 PMID: 16515964 03/07/2006
  • Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. (McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP, Casodex Early Prostate Cancer Trialists' Group) BJU Int 2006 Feb;97(2):247-54 PMID: 16430622 01/25/2006
  • Micro-array analysis of the effect of post-transurethral bladder tumor resection urine on transforming growth factor-beta1 dependent gene expression in transitional cell carcinoma. (Zhang G, Cao Y, Xu Y, See WA) Urol Oncol 2005 Nov-Dec;23(6):413-8 PMID: 16301119 11/23/2005
  • Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. (Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P, Armstrong J, Morris C, 'Casodex' Early Prostate Cancer Trialists Group) Radiother Oncol 2005 Jul;76(1):4-10 PMID: 16145740 09/08/2005
  • BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking. (Chen F, Zhang G, Iwamoto Y, See WA) BMC Urol 2005 May 12;5:8 PMID: 15890073 PMCID: PMC1174876 05/14/2005
  • Elevated 12- and 20-hydroxyeicosatetraenoic acid in urine of patients with prostatic diseases. (Nithipatikom K, Isbell MA, See WA, Campbell WB) Cancer Lett 2006 Feb 28;233(2):219-25 PMID: 15882928 05/11/2005
  • CT urography of urinary diversions with enhanced CT digital radiography: preliminary experience. (Sudakoff GS, Guralnick M, Langenstroer P, Foley WD, Cihlar KL, Shakespear JS, See WA) AJR Am J Roentgenol 2005 Jan;184(1):131-8 PMID: 15615963 12/24/2004
  • Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. (Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K, Casodex Early Prostate Cancer Trialists' Group) J Urol 2004 Nov;172(5 Pt 1):1865-70 PMID: 15540740 11/16/2004
  • Autocrine over expression of fibronectin by human transitional carcinoma cells impairs bacillus Calmette-Guerin adherence and signaling. (Zhang G, Chen F, Xu Y, Cao Y, Crist S, McKerrow A, Iwamoto Y, See WA) J Urol 2004 Oct;172(4 Pt 1):1496-500 PMID: 15371878 09/17/2004
  • Positron emission tomography-computed tomography imaging characteristics of an inferior vena cava tumor thrombus with magnetic resonance imaging correlation. (Rydberg JN, Sudakoff GS, Hellman RS, See WA) J Comput Assist Tomogr 2004 Jul-Aug;28(4):517-9 PMID: 15232383 07/03/2004
  • Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program. (Iversen P, Wirth MP, See WA, McLeod DG, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Lundmo P, Tammela TL, Johansson JE, Morris T, Carroll K, Casodex Early Prostate Cancer Trialists' Group) Urology 2004 May;63(5):928-33 PMID: 15134983 05/12/2004
  • Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. (Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G) Cancer 2004 Apr 15;100(8):1639-45 PMID: 15073851 04/10/2004
  • Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines. (Chen F, Langenstroer P, Zhang G, Iwamoto Y, See W) J Urol 2003 Nov;170(5):2009-13 PMID: 14532843 10/09/2003
  • Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer. (See WA) Curr Treat Options Oncol 2003 Oct;4(5):351-62 PMID: 12941195 08/28/2003
  • Bacillus Calmette-Guerin initiates intracellular signaling in a transitional carcinoma cell line by cross-linking alpha 5 beta 1 integrin. (Chen F, Zhang G, Iwamoto Y, See WA) J Urol 2003 Aug;170(2 Pt 1):605-10 PMID: 12853840 07/11/2003
  • Interleukin-6 production by human bladder tumor cell lines is up-regulated by bacillus Calmette-Guérin through nuclear factor-kappaB and Ap-1 via an immediate early pathway. (Chen FH, Crist SA, Zhang GJ, Iwamoto Y, See WA) J Urol 2002 Aug;168(2):786-97 PMID: 12131369 07/20/2002
  • Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. (See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Vaage S, Tammela TL, Lukkarinen O, Persson BE, Carroll K, Kolvenbag GJ, Casodex Early Prostate Cancer Trialist Group) J Urol 2002 Aug;168(2):429-35 PMID: 12131282 07/20/2002
  • Phase II trial of GM-CSF in advanced prostate cancer. (Dreicer R, See WA, Klein EA) Invest New Drugs 2001;19(3):261-5 PMID: 11561685 09/20/2001
  • Evaluation of gene transfer efficiency by viral vectors to murine bladder epithelium. (Siemens DR, Austin JC, See WA, Tartaglia J, Ratliff TL) J Urol 2001 Feb;165(2):667-71 PMID: 11176455 02/15/2001
  • The bicalutamide Early Prostate Cancer Program. Demography. (See WA, McLeod D, Iversen P, Wirth M) Urol Oncol 2001 Mar;6(2):43-47 PMID: 11166619 02/13/2001
  • Autocrine IL-6 production by human transitional carcinoma cells upregulates expression of the alpha5beta1 firbonectin receptor. (Zhang GJ, Crist SA, McKerrow AK, Xu Y, Ladehoff DC, See WA) J Urol 2000 May;163(5):1553-9 PMID: 10751887 02/07/2001
  • Biomarker distribution after injection into the canine prostate: implications for gene therapy. (Siemens DR, Iwasawa T, Austin JC, Williams RD, See WA, Hedican SP, Tartaglia J, Flynn CM, Cohen MB, Rodgers J, Ratliff TL) BJU Int 2000 Dec;86(9):1076-83 PMID: 11119105 12/19/2000
  • Their initial experience with laparoscopy-assisted cystectomy. (Zayyan KS, See WA) World J Surg 2000 Oct;24(10):1282-3 PMID: 11071477 11/09/2000
  • Continuous antegrade infusion of adriamycin as adjuvant therapy for upper tract urothelial malignancies. (See WA) Urology 2000 Aug 01;56(2):216-22 PMID: 10925081 08/05/2000
  • Tea consumption and risk of bladder and kidney cancers in a population-based case-control study. (Bianchi GD, Cerhan JR, Parker AS, Putnam SD, See WA, Lynch CF, Cantor KP) Am J Epidemiol 2000 Feb 15;151(4):377-83 PMID: 10695596 03/01/2000
  • Distal ureteral regeneration after radical transurethral bladder tumor resection. (See WA) Urology 2000 Feb;55(2):212-5; discussion 215-6 PMID: 10688081 02/25/2000
  • Phase II trial of suramin in patients with metastatic renal cell carcinoma. (Dreicer R, Smith DC, Williams RD, See WA) Invest New Drugs 1999;17(2):183-6 PMID: 10638490 01/19/2000
  • Laparoscopic practice patterns among North American urologists 5 years after formal training. (Colegrove PM, Winfield HN, Donovan JF Jr, See WA) J Urol 1999 Mar;161(3):881-6 PMID: 10022705 02/18/1999
  • Re: Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines. (See WA) J Natl Cancer Inst 1998 Sep 02;90(17):1303 PMID: 9731738 09/10/1998
  • Stable overexpression of TGFbeta1 in a transitional carcinoma cell line: impact on fibronectin production. (Zhang GJ, Ladehoff D, Xu Y, See WA) J Urol 1998 Jul;160(1):230-5 PMID: 9628655 06/17/1998
  • Pledgeted sutures for parenchymal compression facilitate partial nephrectomy. (Mulholland TL, See WA) Br J Urol 1998 Apr;81(4):630-3 PMID: 9598643 05/23/1998
  • Alterations in constituent urinary proteins in response to bladder outlet obstruction in rats. (Burns JA, Kreder KJ, Lubaroff DM, See WA) J Urol 1998 May;159(5):1747-51 PMID: 9554405 04/29/1998
  • Disease-free and overall survival after cryosurgical monotherapy for clinical stages B and C carcinoma of the prostate: a 20-year followup. (Porter MP, Ahaghotu CA, Loening SA, See WA) J Urol 1997 Oct;158(4):1466-9 PMID: 9302144 09/25/1997
  • Future therapies for the treatment of bladder neoplasms. (See WA, Berman CJ) Semin Surg Oncol 1997 Sep-Oct;13(5):376-88 PMID: 9259094 09/01/1997
  • Prognostic implications of extracapsular extension of lymph node metastases in prostate cancer. (Griebling TL, Ozkutlu D, See WA, Cohen MB) Mod Pathol 1997 Aug;10(8):804-9 PMID: 9267823 08/01/1997
  • Continuous infusion, intravesical doxorubicin for the treatment of regionally advanced bladder cancer: a phase I-II trial. (See WA, Dreicer R, Forest PK, Riggs C) Am J Clin Oncol 1997 Aug;20(4):331-7 PMID: 9256884 08/01/1997
  • Surgical resection of metastatic renal cell carcinoma: The University of Iowa experience. (Dreicer R, Galbraith SS, Davis CS, See WA) Urol Oncol 1997 May-Jun;3(3):99-101 PMID: 21227093 05/01/1997
  • Transurethral bladder tumor resection alters fibronectin expression in transitional carcinoma cell lines. (See WA, Xu Y, Gee K, Severson C, Cohen MB, Ladehoff D) J Urol 1997 Mar;157(3):1136-43 PMID: 9072558 03/01/1997
  • Laparoscopic pelvic lymph node dissection following definitive radiotherapy for carcinoma of the prostate. (Lund GO, Winfield HN, Donovan JF, See WA, Loening SA, Williams RD) J Urol 1997 Feb;157(2):548-51 PMID: 8996353 02/01/1997
  • Accuracy of color Doppler sonography in assessing venous thrombus extension in renal cell carcinoma. (Habboub HK, Abu-Yousef MM, Williams RD, See WA, Schweiger GD) AJR Am J Roentgenol 1997 Jan;168(1):267-71 PMID: 8976958 01/01/1997
  • A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer. (Dreicer R, Kemp JD, Stegink LD, Cardillo T, Davis CS, Forest PK, See WA) Cancer Invest 1997;15(4):311-7 PMID: 9246151 01/01/1997
  • Peritoneal venous shunting for the treatment of lymphatic ascites following retroperitoneal lymph node dissection. (See WA, Kresowik TF, Jochimsen PR) Urology 1996 Nov;48(5):783-5 PMID: 8911528 11/01/1996
  • Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. (Dreicer R, Gustin DM, See WA, Williams RD) J Urol 1996 Nov;156(5):1606-8 PMID: 8863548 11/01/1996
  • Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. (Sarosdy MF, Lowe BA, Schellhammer PF, Lamm DL, Graham SD Jr, Grossman HB, See WA, Peabody JO, Moon TD, Flanigan RC, Crawford ED, Morganroth J) Urology 1996 Jul;48(1):21-7 PMID: 8693646 07/01/1996
  • Brachytherapy and continuous infusion 5-fluorouracil for treatment of locally advanced, lymph node negative, prostate cancer: a phase I trial. (See WA, Dreicer R, Wheeler JA, Forest PK, Loening S) Cancer 1996 Mar 01;77(5):924-7 PMID: 8608485 03/01/1996
  • Incidence and management of testicular carcinoma metastatic to the neck. (See WA, Laurenzo JF, Dreicer R, Hoffman HT) J Urol 1996 Feb;155(2):590-2 PMID: 8558666 02/01/1996
  • Radical cystectomy--cornerstone or millstone? (See WA) J Urol 1996 Feb;155(2):504-5 PMID: 8558646 02/01/1996
  • Histopathological features and p53 nuclear protein staining as predictors of survival and tumor recurrence in patients with transitional cell carcinoma of the renal pelvis. (Terrell RB, Cheville JC, See WA, Cohen MB) J Urol 1995 Oct;154(4):1342-7 PMID: 7544836 10/01/1995
  • An outcome study of patient-controlled morphine analgesia, with or without ketorolac, following radical retropubic prostatectomy. (See WA, Fuller JR, Toner ML) J Urol 1995 Oct;154(4):1429-32 PMID: 7658550 10/01/1995
  • Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines. (Lyon PB, See WA, Xu Y, Cohen MB) Prostate 1995 Oct;27(4):179-86 PMID: 7479384 10/01/1995
  • Council-tip catheter facilitates vesicourethral anastomotic suture placement. (See WA) Urology 1995 Sep;46(3):401-2 PMID: 7660518 09/01/1995
  • Commentary on growth factors: the bread-and-butter cytokines of urology. (See WA) J Urol 1994 Dec;152(6 Pt 1):1942 PMID: 7966647 12/01/1994
  • Laparoscopy at the crossroads. (See WA) J Urol 1994 Oct;152(4):1193 PMID: 8072093 10/01/1994
  • Diversity and modulation of plasminogen activator activity in human transitional carcinoma cell lines. (See WA, Yong X, Crist S, Hedican S) J Urol 1994 Jun;151(6):1691-6 PMID: 8189598 06/01/1994
  • Urological laparoscopic practice patterns 1 year after formal training. (See WA, Cooper CS, Fisher RJ) J Urol 1994 Jun;151(6):1595-8 PMID: 8189571 06/01/1994
  • Regulation of plasminogen activator activity in transitional carcinoma cell lines by wound site growth factors. (Xu Y, See WA) Surg Oncol 1994 Jun;3(3):175-85 PMID: 7952402 06/01/1994
  • Predictors of laparoscopic complications after formal training in laparoscopic surgery. (See WA, Cooper CS, Fisher RJ) JAMA 1993 Dec 08;270(22):2689-92 PMID: 8133586 12/08/1993
  • Chest staging in testis cancer patients: imaging modality selection based upon risk assessment as determined by abdominal computerized tomography scan results. (See WA, Hoxie L) J Urol 1993 Sep;150(3):874-8 PMID: 8345604 09/01/1993
  • Plasminogen activators: regulators of tumor cell adherence to sites of lower urinary tract surgical trauma. (See WA) J Urol 1993 Sep;150(3):1024-9 PMID: 8345579 09/01/1993
  • Laparoscopic surgical training: effectiveness and impact on urological surgical practice patterns. (See WA, Fisher RJ, Winfield HN, Donovan JF) J Urol 1993 May;149(5):1054-7 PMID: 8483208 05/01/1993
  • Inverted V peritoneotomy significantly improves nodal yield in laparoscopic pelvic lymphadenectomy. (See WA, Cohen MB, Winfield HN) J Urol 1993 Apr;149(4):772-5 PMID: 8455241 04/01/1993
  • Alpha-fetoprotein half-life as a predictor of residual testicular tumor. Effect of the analytic strategy on test sensitivity and specificity. (See WA, Cohen MB, Hoxie LD) Cancer 1993 Mar 15;71(6):2048-54 PMID: 7680279 03/15/1993
  • Granulomatous inflammation in bladder wash specimens after intravesical bacillus Calmette-Guerin therapy for transitional cell carcinoma of the bladder. (Betz SA, See WA, Cohen MB) Am J Clin Pathol 1993 Mar;99(3):244-8 PMID: 8447285 03/01/1993
  • Staging of advanced bladder cancer. Current concepts and pitfalls. (See WA, Fuller JR) Urol Clin North Am 1992 Nov;19(4):663-83 PMID: 1441024 11/01/1992
  • The impact of iatrogenic urothelial trauma on urinary levels of transforming growth factor-alpha. (Cooper CS, See WA) J Urol 1992 Jun;147(6):1647-9 PMID: 1593715 06/01/1992
  • Tumors of the kidney, ureter, and bladder. (See WA, Williams RD) West J Med 1992 May;156(5):523-34 PMID: 1595278 PMCID: PMC1003316 05/01/1992
  • In vitro particulate adherence to fibronectin: correlation with in vivo particulate adherence to sites of bladder injury. (See WA, Rohlf DP, Crist SA) J Urol 1992 May;147(5):1416-23 PMID: 1569698 05/01/1992
  • Regional chemotherapy for bladder neoplasms using continuous intravesical infusion of doxorubicin: impact of concomitant administration of dimethyl sulfoxide on drug absorption and antitumor activity. (See WA, Xia Q) J Natl Cancer Inst 1992 Apr 01;84(7):510-5 PMID: 1545441 04/01/1992
  • Urothelial injury and clotting cascade activation: common denominators in particulate adherence to urothelial surfaces. (See WA, Williams RD) J Urol 1992 Mar;147(3):541-8 PMID: 1538425 03/01/1992
  • Intravesical recombinant tissue plasminogen activator for the prevention of implantation-mediated bladder tumor recurrence. (See WA) Clin Exp Metastasis 1992 Mar;10(2):99-109 PMID: 1537139 03/01/1992
  • Intracorporeal needle breakage: an unusual complication of papaverine injection therapy for impotence. (Beer SJ, See WA) J Urol 1992 Jan;147(1):148-50 PMID: 1729511 01/01/1992
  • Urinary trypsin levels observed in pancreas transplant patients with duodenocystostomies promote in vitro fibrinolysis and in vivo bacterial adherence to urothelial surfaces. (See WA, Smith JL) Urol Res 1992;20(6):409-13 PMID: 1462479 01/01/1992
  • Antimicrobial tissue penetration in a rat model of E. coli epididymitis. (Tartaglione TA, Taylor TO, Opheim KE, See WA, Berger RE) J Urol 1991 Nov;146(5):1413-7 PMID: 1942312 11/01/1991
  • Urinary levels of activated trypsin in whole-organ pancreas transplant patients with duodenocystostomies. (See WA, Smith JL) Transplantation 1991 Oct;52(4):630-3 PMID: 1926341 10/01/1991
  • Urological laparoscopic surgery. (Winfield HN, Donovan JF, See WA, Loening SA, Williams RD) J Urol 1991 Oct;146(4):941-8 PMID: 1680202 10/01/1991
  • Regional chemotherapy using continuous intravesical infusion doxorubicin for the treatment of muscle invasive transitional cell bladder carcinoma in a rat model. (See WA, Xia Q, McDermott T, Williams RD) J Urol 1991 Oct;146(4):1147-52 PMID: 1895443 10/01/1991
  • Ectopic ureter: a rare cause of purulent vaginal discharge. (See WA, Mayo M) Obstet Gynecol 1991 Sep;78(3 Pt 2):552-5 PMID: 1870821 09/01/1991
  • A continuous intravesical drug delivery system for the rat. (See WA, McDermott T, Xia Q, Williams RD) J Urol 1991 Mar;145(3):596-9 PMID: 1997716 03/01/1991
  • Single-dose cyclophosphamide for the prevention of bladder tumor implantation in F344 rats: site of drug activity. (See WA, Crist SA, Williams RD) Cancer Res 1991 Mar 01;51(5):1378-83 PMID: 1997176 03/01/1991
  • Single-dose preoperative systemic cyclophosphamide for the prevention of bladder tumor implantation in F344 rats. (See WA, Crist SA, Boileau MA, Williams RD) Cancer Res 1991 Mar 01;51(5):1373-7 PMID: 1997175 03/01/1991
  • Activated proteolytic enzymes in the urine of whole organ pancreas transplant patients with duodenocystostomy. (See WA, Smith JL) Transplant Proc 1991 Feb;23(1 Pt 2):1615-6 PMID: 1989308 02/01/1991
  • Lower urinary tract complications in patients with duodenocystostomies for exocrine drainage of the transplanted pancreas. (Smith JL, See WA, Ames SA, Piper JB, Corry RJ) Transplant Proc 1991 Feb;23(1 Pt 2):1611-2 PMID: 1989307 02/01/1991
  • Bacterial epididymitis in the rat: a model for assessing the impact of acute inflammation on epididymal antibiotic penetration. (See WA, Taylor TO, Mack LA, Tartaglione TA, Opheim KE, Berger RE) J Urol 1990 Sep;144(3):780-4 PMID: 2201798 09/01/1990
  • Kinetics of transitional tumor cell line 4909 adherence to injured urothelial surfaces in F-344 rats. (See WA, Chapman PH, Williams RD) Cancer Res 1990 Apr 15;50(8):2499-504 PMID: 2317832 04/15/1990
  • Pathophysiology of transitional tumor cell adherence to sites of urothelial injury in rats: mechanisms mediating intravesical recurrence due to implantation. (See WA, Miller JS, Williams RD) Cancer Res 1989 Oct 01;49(19):5414-8 PMID: 2766306 10/01/1989
  • Scrotal ultrasonography: a predictor of complicated epididymitis requiring orchiectomy. (See WA, Mack LA, Krieger JN) J Urol 1988 Jan;139(1):55-6 PMID: 3275802 01/01/1988
  • Heparin prevention of tumor cell adherence and implantation on injured urothelial surfaces. (See WA, Chapman PH) J Urol 1987 Jul;138(1):182-6 PMID: 2955131 07/01/1987
  • Tumor cell implantation following neodymium-YAG bladder injury: a comparison to electrocautery injury. (See WA, Chapman WH) J Urol 1987 Jun;137(6):1266-9 PMID: 3586172 06/01/1987
  • Last update: 07/26/2016
    jenkins-FCD Prod-130 96200611f8481f0aa4f84230b11dd74d063847a3